Low risk — use of or exposure to this product is not likely to cause adverse health consequences.
Nicorette Lozenge and NicoDerm CQ Recalled by GlaxoSmithKline Consumer Healthcare; dba-GlaxoSmithKline Due to Failed Lozenge Specifications; Lozenges are overly thick, overly...
What You Should Do
Stop using this product immediately. Do not consume, use, or distribute it.
Return the product to the place of purchase for a full refund. If you have questions, contact GlaxoSmithKline Consumer Healthcare; dba-GlaxoSmithKline directly.
Affected Products
Nicorette Lozenge and NicoDerm CQ, nicotine polacrilex system. 189 2mg Mint Flavored Lozenges + 21 31 mg Patches. OTC Only. GlaxoSmithKlein, 1000 GSK Drive, Moon Township, PA 15108. UPC: 0-03-0766-1480-30-2.
Quantity: 150 cases
Why Was This Recalled?
Failed Lozenge Specifications; Lozenges are overly thick, overly soft, and sub and superpotent.
Where Was This Sold?
This product was distributed nationwide across all 50 states.
About GlaxoSmithKline Consumer Healthcare; dba-GlaxoSmithKline
GlaxoSmithKline Consumer Healthcare; dba-GlaxoSmithKline has 10 total recalls tracked by RecallDetector.
Related Recalls
Icosapent Ethyl Capsules Recalled by Zydus Pharmaceuticals (USA) Inc Due to Failed Tablet/Capsule specifications: Red dots inside capsule and...
Zydus Pharmaceuticals (USA) Inc · March 9, 2026
Product label: Temozolomide Capsules Recalled by Rising Pharma Holding, Inc. Due to Failed Impurities/Degradation Specifications: An out-of-specification result observed during...
Rising Pharma Holding, Inc. · March 3, 2026
Semaglutide Inj. Recalled by New Life Pharma LLC Due to Lack of Assurance of Sterility
New Life Pharma LLC · February 26, 2026
Tirzepatide Inj Recalled by New Life Pharma LLC Due to Lack of Assurance of Sterility
New Life Pharma LLC · February 26, 2026
Tirzepatide Inj Recalled by New Life Pharma LLC Due to Lack of Assurance of Sterility
New Life Pharma LLC · February 26, 2026
Data sourced from the FDA (Drug). Last updated March 26, 2026. View original report